---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-092957"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2025-09-24T23:59:59+00:00"
generated_at: "2026-05-17T05:48:18.683301+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Immuneering signs $25M Sanofi placement contingent on public offering; Phase 2a pancreatic data shows 86% OS

## Summary
- Sanofi subsidiary Aventis agrees to purchase $25M in stock at public offering price; closing contingent on $75M+ public offering by Sept 26, 2025.
- Updated Phase 2a atebimetinib + mGnP data in 1L pancreatic cancer (N=34): 86% OS at 9 mos (vs ~47% SOC), median PFS 9.6 mos, median OS not reached.
- Safety profile: Grade ≥3 TEAEs in ≥10% were anemia (24%) and neutropenia (18%); no Grade 5 events.
- Near-term milestones: regulatory feedback on Phase 3 plans in Q4 2025; potential Phase 3 start by end 2025 and first patient by mid-2026.
- Leerink Partners and Oppenheimer & Co. act as joint bookrunners for the public offering and placement agents for private placement.

## SEC filing metadata
- accession: 0001104659-25-092957
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2025-09-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000110465925092957/0001104659-25-092957-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000110465925092957/tm2526843d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-092957
- JSON: https://secwatch.observer/filing/0001104659-25-092957.json
- Plain text: https://secwatch.observer/filing/0001104659-25-092957.txt

## Key facts
- Equity Issuances
  Immuneering Corp issued $25.0 million of shares of the Company's Class A common stock or, in certain circumstances, shares of the Company's non-voting Class B common stock of common stock to Aventis Inc. for The price per Share will be the price per share of Class A Common Stock to the public in the Public Offering as set forth on the cover of the definitive prospec.
  - Security: common stock
  - Shares: $25.0 million of shares of the Company's Class A common stock or, in certain circumstances, shares of the Company's non-voting Class B common stock
  - Purchaser: Aventis Inc.
  - Consideration: The price per Share will be the price per share of Class A Common Stock to the public in the Public Offering as set forth on the cover of the definitive prospec
  source text: On September 24, 2025, Immuneering Corporation (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with Aventis Inc. (the "Investor"), a wholly owned subsidiary of Sanofi, a French société anonyme, pursuant to which the Company, in a private placement transaction (the "Private Placement"), agreed to issue and sell to the Investor $25.0 million of shares (the "Class A Shares") of the Company's Class A common stock, par value $0.001 per share ("Class A Common Stock"), or in certain circumstances in lieu of Class A Shares, shares (the "Class B Shares" and, together with the Class A Shares, collectively, the "Shares") of the Company's non-voting Class B common stock, par value $0.001 per share ("Class B Common Stock"), subject to and contingent upon the closing of a firm commitment underwritten public offering of Class A Common Stock by the Company that results in gross proceeds to the Company of at least $75.0 million and the pricing of which is publicl
  evidence_url: https://www.sec.gov/Archives/edgar/data/1790340/000110465925092957/0001104659-25-092957-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.